A recent study identified that HLA-E suppresses NK cell sensitivity to tumor cells and that resistance to immune checkpoint blockade therapy in multiple clinical studies correlates with an NK sensitivity gene signature, including HLA-E (51). Here, HLA-E is linked to neoplasm.